Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide
| Autor: | Tomoko Ichiki, John C. Burnett, Nina Dzhoyashvili |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.drug_class
030204 cardiovascular system & hematology Pharmacology Cenderitide Article 03 medical and health sciences 0302 clinical medicine Drug Development Natriuretic peptide Medicine Humans 030212 general & internal medicine Receptor Natriuretic Peptides Heart Failure business.industry Activator (genetics) medicine.disease Dendroaspis natriuretic peptide Drug development Heart failure Drug Design Cardiology and Cardiovascular Medicine business Guanylate cyclase Snake Venoms |
| Zdroj: | International journal of cardiology. 281 |
| ISSN: | 1874-1754 |
| Popis: | Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to co-activate the two NP receptors, particulate guanylyl cyclase (pGC)-A and pGC-B. The rationale for its design was to achieve the renal-enhancing and anti-fibrotic properties of dual receptor activation, but without clinically significant hypotension. Here, we review the biology of the NPs and the rationale for their use in heart failure. Most importantly, we present the key studies related to the discovery of Cenderitide. Finally, we review the key clinical studies that have advanced this first-in-class dual NP receptor activator for heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect